Biosimilar and generic formulations of novel antidiabetic drugs: the role of liraglutide in clinical pharmacology of type 2 diabetes

Expert Rev Clin Pharmacol. 2022 Jul;15(7):795-797. doi: 10.1080/17512433.2022.2108400. Epub 2022 Aug 4.

Manfredi Rizzo¹, Francesco Cosentino², Christos Mantzoros^{3

4}

¹ Department of Health Promotion Sciences Maternal and Infantile Care, Internal Medicine and Medical Specialties (Promise), School of Medicine, University of Palermo, Palermo, Italy.
² Division of Cardiology, Department of Medicine, Karolinska Institute and Karolinska University Hospital, University of Stockholm, Stockholm, Sweden.
³ Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.
⁴ Section of Endocrinology, Boston VA Healthcare System, Harvard Medical School, Boston, MA, USA.

No abstract available

Keywords: Biosimilar; GLP-1; diabetes; generics; liraglutide; treatment.

Publication types